Stereotactic arrhythmia radioablation: A novel therapy for cardiac arrhythmia

Heart Rhythm. 2023 Sep;20(9):1327-1336. doi: 10.1016/j.hrthm.2023.04.052. Epub 2023 May 5.

Abstract

Cardiac arrhythmia is a global health problem, and catheter ablation has been one of its main treatments for decades. However, catheter ablation is an invasive method that cannot reach the deep myocardium, and it carries a considerable risk of side effects and recurrence. Therefore, it is necessary to explore a novel approach. Stereotactic body radiotherapy, which has been widely used in the field of radiation oncology, has recently expanded in the treatment of cardiac arrhythmia; when used in this context, it is known as stereotactic arrhythmia radioablation (STAR). As a noninvasive, effective, and well-tolerated treatment, STAR may be a suitable alternative method for patients with cardiac arrhythmia who are resistant or intolerant to catheter ablation. The main particles used to deliver energy in STAR are photons, protons, and carbon ions. Most studies have shown the short-term effectiveness of STAR, but problems such as a high long-term recurrence rate with a cumulative ventricular tachycardia-free survival rate from the published literature of 38.6% and related complications have also emerged. Therefore, in this article, we review the application of stereotactic body radiotherapy in cardiac arrhythmia, analyze its potential problems, and explore methods for improvement.

Keywords: Atrial fibrillation; Cardiac arrhythmia; Stereotactic arrhythmia radioablation; Stereotactic body radiotherapy; Ventricular tachycardia.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arrhythmias, Cardiac / etiology
  • Catheter Ablation* / adverse effects
  • Catheter Ablation* / methods
  • Humans
  • Myocardium
  • Radiosurgery* / adverse effects
  • Radiosurgery* / methods
  • Tachycardia, Ventricular*